Associations between plasma insulin-like growth factor proteins and c-peptide and quality of life in patients with metastatic colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 6, 2005, Pages 1402-1410

  Meyerhardt, Jeffrey A ^a,i   Sloan, Jeffrey A ^b   Sargent, Daniel J ^b   Goldberg, Richard M ^c   Pollak, Michael ^d   Morton, Roscoe F ^e   Ramanathan, Ramesh K ^f   Williamson, Stephen K ^g   Findlay, Brian P ^h   Fuchs, Charles S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e Iowa Oncology Research Association Community Clinical Oncology Program   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h Institut national du cancer du Canada   (Canada)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; APPETITE; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; COUGHING; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PAIN PARAMETERS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPETITE; C-PEPTIDE; COHORT STUDIES; COLORECTAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; PATIENT SATISFACTION; QUALITY OF LIFE; SOMATOMEDINS; STRESS, PSYCHOLOGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 20444389782     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0862     Document Type: Article

References (65)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
3. Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer 2003;39:287-94.
4. Sloan JA, McLeod H, Sargent D, et al. Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL) [abstract no. 5]. Proc Meet Am Soc Clin Oncol 2004;23.
5. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
6. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996;5:1013-5.
7. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
8. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54.
9. Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53.
10. Rechler MM. Growth inhibition by insulin-like growth factor (IGF) binding protein-3-what's IGF got to do with it? Endocrinology 1997;138:2645-7.
11. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
12. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5.
13. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:345-9.
14. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002;50:642-6.
15. Hunt KJ, Toniolo P, Akhmedkhanov A, et al. Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2002;11:901-5.
16. Probst-Hensch NM, Yuan JM, Stanczyk FZ, et al. IGF-1, IGF-II and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001;85:1695-9.
17. Unden AL, Elofsson S, Knox S, Lewitt MS, Brismar K. IGF-I in a normal population: relation to psychosocial factors. Clin Endocrinol (Oxf) 2002;57:793-803.
18. Thompson JL, Butterfield GE, Gylfadotrir UK, et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 1998;83:1477-84.
19. Trojan DA, Collet J, Pollak MN, et al. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. J Neurol Sci 2001;182:107-15.
20. Aleman A, Verhaar HJ, De Haan EH, et al. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab 1999;84:471-5.
21. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000;35:647-54.
22. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996;77:200-2.
23. Lloyd ME, Hart DJ, Nandra D, et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population: the Chingford study. Ann Rheum Dis 1996;55: 870-4.
24. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
25. Goldberg R, Morton R, Sargent D, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol Abstr 511. Orlando, FL, 2002.
26. Fuchs C, Pollak M, Sargent DJ, et al. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): results from Intergroup Trial N9741 [abstract no. 3521]. Proc Meet Am Soc Clin Oncol 2004;23.
27. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
28. Pollak M, Costantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer fast 1990;82:1693-7.
29. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
30. Giovannucci E, Rimm EB, Liu Y, Willett WC. Height, predictors of C-peptide and cancer risk in men. Int J Epidemiol 2004;33:217-25.
31. Sloan JA, Aaronson N, Cappelleri JC, Fairclough DL, Varricchio C. Assessing the clinical significance of single items relative to summated scores. Mayo Clin Proc 2002;77:479-87.
32. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol 1998;16:3662-73.
33. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978;1:373-8.
34. McCorkle R, Quint-Benoliel J. Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 1983;17:431-8.
35. McCorkle R, Benoliel JQ, Donaldson G, et al. A randomized clinical trial of home nursing care for lung cancer patients. Cancer 1989;64:1375-82.
36. Peruselli C, Camporesi E, Colombo AM, et al. Quality-of-life assessment in a home care program for advanced cancer patients: a study using the Symptom Distress Scale. J Pain Symptom Manage 1993;8:306-11.
37. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 1995;10:423-31.
38. Cohen J. Statistical power analysis for the behavioral sciences. New Jersey: Lawrence Erlbaum Associates; 1988.
39. Van LL, Daviglus ML, Liu K, et al. BMI and health-related quality of life in adults 65 years and older. Obes Res 2004;12:69-76.
40. Hassan MK, Joshi AV, Madhavan SS, Amonkar MM. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord 2003;27:1227-32.
41. Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 2000;160:861-8.
42. Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. Ann Surg 1983;197:152-62.
43. Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96.
44. Carroll PV, Littlewood R, Weissberger AJ, et al. The effects of two doses of replacement growth hormone on the biochemical, body composition and psychological profiles of growth hormone-deficient adults. Eur J Endocrinol 1997;137:146-53.
45. Soares CN, Musolino NR, Cunha Neto M, et al. Impact of recombinant human growth hormone (RH-GH) treatment on psychiatric, neuropsychological and clinical profiles of GH deficient adults. A placebo-controlled trial. Arq Neuropsiquiatr 1999;57:182-9.
46. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997;49:1621-30.
47. Waters D, Danska J, Hardy K, et al. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:865-72.
48. Lee PD, Pivarnik JM, Bukar JG, et al. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1996;81:2968-75.
49. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
50. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 1995;80:443-9.
51. Heald AH, Cade JE, Cruickshank JK, et al. The influence of dietary intake on the insulin-like growth factor (IGF) system across three ethnic groups: a population-based study. Public Health Nutr 2003;6:175-80.
52. Soliman AT, Hassan AE, Aref MK, et al. Serum insulin-like growth factors I and II concentrations and growth hormone and insulin responses to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res 1986;20:1122-30.
53. Dean DJ, Gazdag AC, Wetter TJ, Cartee GD. Comparison of the effects of 20 days and 15 months of calorie restriction on male Fischer 344 rats. Aging (Milano) 1998;10:303-7.
54. Zuniga-Guajardo S, Garfinkel PE, Zinman B. Changes in insulin sensitivity and clearance in anorexia nervosa. Metabolism 1986;35:1096-100.
55. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-52.
56. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002;106: 939-44.
57. Mitry E, Douillard JY, Van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004;15:1013-7.
58. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 2004;22:648-57.
59. Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer results from cancer and leukemia group B study 8541. J Clin Oncol 1996;14:3000-8.
60. Holdaway IM, Mason BH, Lethaby AE, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 2003;73:905-8.
61. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group. J Clin Oncol 1992;10:1833-8.
62. Coates AS, Hurny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 2000;18:3768-74.
63. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: 1407-18.
64. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64.
65. Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 2004;31:54-63.